European Management Platform for Childhood Interstitial Lung Diseases - chILD-EU Register and Biobank

Child Clinical Trial

— chILD-EU  

Official title:

Orphans Unite: chILD Better Together - European Management Platform for Childhood Interstitial Lung Diseases / chILD-EU - International Register and Biobank for Children´s Interstital Lung Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02852928
• Other study ID #: chILD-EU
• Status: Recruiting
• Start date: December 2013
• Est. completion date: December 2029

Study information

• Verified date: September 2022
• Source: Ludwig-Maximilians - University of Munich
• Contact: Matthias Griese, Prof.
• Phone: +49/89/440057871
• Email: Matthias.Griese[@]med.uni-muenchen.de
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Generation of a common European database and biobank Continous assessment and implementation of guidelines and treatment protocols Establishment of a large observational cohort of chILD patients Determination the value of outcomes used in child Assess treatment variations used, deliver data from defined protocols and linked outcomes

Description:

Objective 1: Generation of a common European database and biobank. The existing national programmes to collect data on chILD in three countries (France, Germany, UK) will enable the consortium to swiftly adapt current frameworks to a functionally appropriate pan-European web-based database and biobank. Importantly, compatibility with ongoing United States chILD data base developments will be factored in. Objective 2: Continuous assessment and implementation of guidelines and treatment protocols. Our Standards Working Group will convene regularly. Initial tasks will establish (a) specific diagnostic pathways, including detailed protocols for gathering clinical information, blood testing, imaging and pathology ("Best Practice Checklist"); (b) international panels of clinicians, geneticists, radiologists and pathologists who will review every diagnosis to quality control the data; and (c) detailed protocols for follow up to generate natural history data. Objective 3: Recruitment of a carefully characterized cohort of chILD patients. European wide recruitment and interdisciplinary critical peer review of all diagnoses submitted from across Europe is imperative. Each case will be given a diagnosis independently; if no firm diagnosis is possible, we will review the case periodically as new information becomes available. During the first year of the study, clinicians´ decisions according to local practice and outcomes will be independently monitored and assessed. Objective 4: Determine the value of outcomes used in chILD. We will systematically optimize and clarify the relative weight of a large spectrum of single and composite clinical outcomes (using both clinician and carer scoring), sequential limited chest CT (to minimise radiation exposure), lung function testing, histopathological categorization of lung biopsies, serum markers and genetic tests. Variability, reproducibility and the effects of training on reading images will be investigated. Objective 5: Assess treatment variations used, deliver data from defined protocols and linked outcomes. This project will analyse in detail treatment and outcomes within and between subjects using data collected. Analysis of the collected data will enable us to support the definition of trial protocols planned in the future.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1000
• Est. completion date: December 2029
• Est. primary completion date: December 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• all children with suspected or
• verified diagnosis of ILD or
• masquerading as ILD and
• those with rare localized parenchymal lung diseases

Exclusion Criteria:

• other indication as inclusion criteria

Related Conditions & MeSH terms

• Child
• Eosinophilia
• Lung Diseases
• Lung Diseases, Interstitial
• Pulmonary Alveolar Proteinosis
• Pulmonary Eosinophilia
• Pulmonary Fibrosis
• Respiratory Distress Syndrome
• Respiratory Distress Syndrome, Newborn

Locations

Country	Name	City	State
Germany	Medizinische Hochschule Hannover	Hannover	Niedersachsen
Turkey	Hacettepe University, Medical Faculty	Ankara	Sihhiye
United Kingdom	University of Edinburgh	Edinburgh

Sponsors (1)

Lead Sponsor	Collaborator
Matthias Griese

Countries where clinical trial is conducted

Germany,  Turkey,  United Kingdom, 

References & Publications (1)

Griese M, Seidl E, Hengst M, Reu S, Rock H, Anthony G, Kiper N, Emiralioglu N, Snijders D, Goldbeck L, Leidl R, Ley-Zaporozhan J, Krüger-Stollfuss I, Kammer B, Wesselak T, Eismann C, Schams A, Neuner D, MacLean M, Nicholson AG, Lauren M, Clement A, Epaud R, de Blic J, Ashworth M, Aurora P, Calder A, Wetzke M, Kappler M, Cunningham S, Schwerk N, Bush A; the other chILD-EU collaborators. International management platform for children's interstitial lung disease (chILD-EU). Thorax. 2018 Mar;73(3):231-239. doi: 10.1136/thoraxjnl-2017-210519. Epub 2017 Oct 22. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Included subjects with specific diagnosis	Number of recruited subjects	10 years
Secondary	Survial	Survival of the participants	10 years

External Links

•   chILD-EU project website